Vaccine cuts symptomatic Covid-19 cases by 94% — Israeli study

Israel’s largest healthcare provider on Sunday reported a 94 per cent drop in symptomatic COVID-19 infections among 600,000 people who received two doses of the Pfizer’s vaccine in the country’s biggest study to date.

Health maintenance organization (HMO) Clalit, which covers more than half of all Israelis, said the same group was also 92 per cent less likely to develop severe illness from the virus.

The study worked with a group of the same size, with matching medical histories, who had not received the vaccine. It compared 600,000 people who received both doses of the Pfizer vaccine against a same-sized group with matching medical histories who had not received the vaccine yet.

Israel has been rapidly vaccinating its population, and the new study underscores how effective the vaccine is, as the data nearly matches Pfizer’s Phase three clinical trial that showed the vaccine to be 95 per cent effective.

“It shows unequivocally that Pfizer’s coronavirus vaccine is extremely effective in the real world a week after the second dose, just as it was found to be in the clinical study,” said Ran Balicer, Clalit’s chief innovation officer.

The Pfizer vaccine requires two doses.

He added that the data indicates the Pfizer vaccine, which was developed in partnership with Germany’s BioNTech, is even more effective two weeks or more after the second shot.

Researchers at the Weizmann Institute of Science, who have been tabulating national data, said on Sunday that a sharp decline in hospitalisation and serious illness identified earlier among the first age group to be vaccinated – aged 60 or older – was seen for the first time in those aged 55 and older.

Hospitalisations and serious illness were still rising in younger groups who began vaccinations weeks later.

Israel has been conducting a rapid vaccine rollout and its database offers insights into vaccine effectiveness and at what point countries might attain herd immunity.